New drug duo takes on tough breast cancer

NCT ID NCT07244874

Not yet recruiting Disease control Sponsor: Tianjin Medical University Cancer Institute and Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests a combination of two drugs—Sacituzumab Tirumotecan and Toripalimab—as a first treatment for people with a specific type of advanced triple-negative breast cancer that is PD-L1 positive. The study aims to see if the combo shrinks tumors and improves survival. About 41 participants will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Sacituzumab tirumotecan and toripalimab

What this could lead to

If successful, this combination could offer a new first-line treatment option for people with a hard-to-treat form of advanced breast cancer.

What could go wrong

This is a small, early-phase study with only 41 participants, so results may not apply to everyone. The combination may cause side effects or not improve outcomes enough.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TNBC, TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PD-L1 POSITIVE TNBC, TRIPLE NEGATIVE BREAST CANCER